Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.2, 2010-02, pp. : 195-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advantages of atypical antipsychotics in the maintenance treatment of schizophrenia

By Kissling W.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 188-188

Elsevier

Access to resources Recommend Favorite

Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents

By Paz Toren Sharon Ratner Nathaniel Laor Abraham Weizman

Drug Safety, Vol. 27, Iss. 14, 2004-01 ,pp. : 1135-1156

Adis International

Access to resources Recommend Favorite

Treatment Options for Juvenile-Onset Systemic Lupus Erythematosus

By Carreño L. López-Longo F.J. González C.M. Monteagudo I.

Pediatric Drugs, Vol. 4, Iss. 4, 2002-01 ,pp. : 241-256

Adis International

Access to resources Recommend Favorite

Role of Newer Atypical Antipsychotics in the Management of Treatment- Resistant Schizophrenia

By Emsley R.A.

CNS Drugs, Vol. 13, Iss. 6, 2000-06 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

Advances in Atypical Antipsychotics for the Treatment of Schizophrenia: New Formulations and New Agents

By Kelleher J.P. Centorrino F. Albert M.J. Baldessarini R.J.

CNS Drugs, Vol. 16, Iss. 4, 2002-01 ,pp. : 249-261

Adis International

Access to resources Recommend Favorite